MedTrace Logo

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2012-05-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of six intravenous (IV) infusions of magnesium chloride versus placebo in patients who have residual muscle weakness from a stroke that occurred three months to four years ago.

Conditions

Interventions

DRUG

Magnesium Chloride

An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen

DRUG

Placebo

A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent

Sponsors & Collaborators

  • Relox Medical, LLC

    lead INDUSTRY

Principal Investigators

  • Bert Spilker, PhD, MD · President, Bert Spilker & Associates, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-05-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00933868 on ClinicalTrials.gov